Profile data is unavailable for this security.
About the company
BrightGene Bio-Medical Technology Co Ltd is a China-based company mainly engaged in the research and development, production and sales of raw materials, pharmaceutical intermediates and preparations, as well as providing related technology transfer. The Company's products mainly cover therapeutic areas such as antiviral, antifungal, immunosuppression, respiratory system, anti-tumor and metabolism. Core products in the antiviral field include antifungal active pharmaceutical ingredients (APIs), Oseltamivir and others. The core products in the antifungal field include Caspofungin, Micafungin Sodium, Anidulafungin, Posaconazole. Core products in the immunosuppression field include Everolimus, Pimecrolimus and others. Core products in the respiratory system include Budesonide, Salmeterol, Fluticasone, and Tiotropium. Core products in the anti-tumor field include Eribulin and Lubitidin. Core products in the metabolic field include the Innovative drug BGM0504.
- Revenue in CNY (TTM)1.18bn
- Net income in CNY62.08m
- Incorporated2001
- Employees1.15k
- LocationBrightGene Bio-Medical Technology Co LtdBuilding C25-28, No.218 Xinghu Road, SipSUZHOU 215123ChinaCHN
- Phone+86 51 262620988
- Fax+86 51 262551799
- Websitehttps://www.bright-gene.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jinyu Bio-Technology Co Ltd | 1.33bn | 100.76m | 17.22bn | 1.74k | 218.17 | 3.15 | -- | 12.98 | 0.071 | 0.071 | 1.27 | 4.92 | 0.1946 | 2.45 | 1.89 | 762,676.30 | 1.37 | 4.31 | 1.56 | 5.06 | 50.46 | 57.76 | 7.02 | 17.99 | 3.09 | -- | 0.0029 | 36.89 | -21.45 | 2.19 | -61.57 | -13.19 | -21.84 | -12.94 |
| Tonghua Dongbao Pharmaceutical Co Ltd | 2.74bn | 1.23bn | 17.41bn | 3.41k | 14.18 | 2.44 | -- | 6.35 | 0.6271 | 0.6271 | 1.40 | 3.64 | 0.3589 | 1.05 | 5.11 | 803,924.60 | 15.84 | 14.89 | 17.08 | 15.68 | 71.05 | 78.86 | 44.15 | 35.26 | 3.49 | -- | 0.0988 | 50.60 | -34.66 | -6.27 | -103.66 | -- | 14.17 | 4.56 |
| Shandong Buchang Pharmaceuticals Co Ltd | 10.96bn | 1.66m | 18.32bn | 7.69k | 2,546.92 | 1.73 | -- | 1.67 | 0.0068 | 0.0068 | 10.34 | 10.03 | 0.5519 | 0.9196 | 13.73 | 1,425,409.00 | -0.6503 | 0.8521 | -0.9366 | 1.25 | 62.31 | 70.57 | -1.18 | 1.32 | 0.4929 | 3.23 | 0.2758 | 157.32 | -16.91 | -5.04 | -273.62 | -- | -21.53 | -- |
| Liaoning Cheng Da Co Ltd | 11.12bn | 862.79m | 18.68bn | 3.32k | 21.24 | 0.6349 | -- | 1.68 | 0.575 | 0.575 | 7.27 | 19.23 | 0.2277 | 5.72 | 5.88 | 3,352,748.00 | 2.94 | 3.15 | 4.13 | 4.55 | 12.07 | 13.95 | 12.89 | 9.88 | 0.9357 | -- | 0.2586 | 16.44 | 4.70 | -8.65 | -10.09 | -29.33 | -9.31 | -27.52 |
| China Resources Dubl-Crne Phrmctl Co Ltd | 10.95bn | 1.58bn | 19.42bn | 13.41k | 12.20 | 1.72 | -- | 1.77 | 1.53 | 1.53 | 10.62 | 10.90 | 0.6524 | 2.99 | 5.05 | 816,058.20 | 9.70 | 8.90 | 13.45 | 11.99 | 56.61 | 57.39 | 14.86 | 13.13 | 1.75 | -- | 0.0904 | 33.53 | -0.8711 | 3.63 | -2.19 | 9.06 | 21.41 | 9.15 |
| BrightGene Bio-Medical Technology Co Ltd | 1.18bn | 62.08m | 19.57bn | 1.15k | 310.62 | 8.00 | -- | 16.59 | 0.1489 | 0.1489 | 2.82 | 5.79 | 0.2305 | 1.61 | 3.38 | 1,025,174.00 | 0.5058 | 5.25 | 0.6383 | 6.47 | 51.53 | 56.22 | 2.19 | 17.55 | 0.9402 | 1.23 | 0.4935 | 21.32 | 8.74 | 20.58 | -6.57 | 11.23 | 23.50 | 3.20 |
| Joincare Pharmaceutical Group Ind. Co. | 15.20bn | 1.37bn | 21.40bn | 14.35k | 15.78 | 1.44 | -- | 1.41 | 0.7413 | 0.7413 | 8.24 | 8.13 | 0.4211 | 2.40 | 5.51 | 1,059,126.00 | 8.29 | 8.60 | 17.45 | 18.66 | 61.28 | 62.42 | 19.70 | 17.66 | 2.38 | -- | 0.1776 | 27.59 | -6.17 | 5.45 | -3.90 | 9.17 | 6.84 | 4.56 |
| Tasly Pharmaceutical Group Co Ltd | 8.35bn | 1.10bn | 22.38bn | 10.96k | 20.39 | 1.82 | -- | 2.68 | 0.7348 | 0.7348 | 5.59 | 8.24 | 0.525 | 1.83 | 7.50 | 761,658.60 | 6.44 | 5.86 | 7.91 | 7.26 | 65.70 | 58.62 | 12.26 | 10.61 | 3.12 | -- | 0.0642 | 56.80 | -2.03 | -14.86 | -10.78 | -0.9327 | -5.02 | 9.94 |
| Holder | Shares | % Held |
|---|---|---|
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2025 | 4.11m | 0.97% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 3.59m | 0.85% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 3.02m | 0.71% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 2.86m | 0.68% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2025 | 2.18m | 0.52% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 2.03m | 0.48% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 1.70m | 0.40% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 1.61m | 0.38% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 1.22m | 0.29% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 1.20m | 0.29% |
